1. Home
  2. NOAH vs RGNX Comparison

NOAH vs RGNX Comparison

Compare NOAH & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOAH
  • RGNX
  • Stock Information
  • Founded
  • NOAH 2005
  • RGNX 2008
  • Country
  • NOAH China
  • RGNX United States
  • Employees
  • NOAH N/A
  • RGNX N/A
  • Industry
  • NOAH Investment Managers
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NOAH Finance
  • RGNX Health Care
  • Exchange
  • NOAH Nasdaq
  • RGNX Nasdaq
  • Market Cap
  • NOAH 683.3M
  • RGNX 661.2M
  • IPO Year
  • NOAH 2010
  • RGNX 2015
  • Fundamental
  • Price
  • NOAH $10.30
  • RGNX $11.86
  • Analyst Decision
  • NOAH Buy
  • RGNX Strong Buy
  • Analyst Count
  • NOAH 1
  • RGNX 7
  • Target Price
  • NOAH $11.50
  • RGNX $30.29
  • AVG Volume (30 Days)
  • NOAH 80.5K
  • RGNX 537.9K
  • Earning Date
  • NOAH 11-25-2025
  • RGNX 11-06-2025
  • Dividend Yield
  • NOAH 5.67%
  • RGNX N/A
  • EPS Growth
  • NOAH N/A
  • RGNX N/A
  • EPS
  • NOAH 0.75
  • RGNX N/A
  • Revenue
  • NOAH $360,100,505.00
  • RGNX $161,318,000.00
  • Revenue This Year
  • NOAH N/A
  • RGNX $198.02
  • Revenue Next Year
  • NOAH $5.17
  • RGNX $2.67
  • P/E Ratio
  • NOAH $13.67
  • RGNX N/A
  • Revenue Growth
  • NOAH N/A
  • RGNX 91.30
  • 52 Week Low
  • NOAH $7.67
  • RGNX $5.04
  • 52 Week High
  • NOAH $13.30
  • RGNX $13.93
  • Technical
  • Relative Strength Index (RSI)
  • NOAH 28.46
  • RGNX 53.04
  • Support Level
  • NOAH $10.52
  • RGNX $10.70
  • Resistance Level
  • NOAH $10.87
  • RGNX $12.05
  • Average True Range (ATR)
  • NOAH 0.23
  • RGNX 0.73
  • MACD
  • NOAH -0.07
  • RGNX -0.10
  • Stochastic Oscillator
  • NOAH 11.90
  • RGNX 79.32

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: